Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dovitinib companion diagnostic - Allarity Therapeutics

Next Previous
Drug Profile

Dovitinib companion diagnostic - Allarity Therapeutics

Alternative Names: Dovitinib DRP®; Dovitinib DRP® companion diagnostic

Latest Information Update: 09 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oncology Venture
  • Developer Allarity Therapeutics
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer; Endometrial cancer; Gastrointestinal stromal tumours; Renal cancer

Most Recent Events

  • 09 Jan 2025 No development reported - Phase-III for Renal cancer (Diagnosis) in Japan, Hungary, France, Norway, Austria, Saudi Arabia, Netherlands, United Kingdom, Canada, Italy, Brazil, Spain, Greece, Sweden, Germany, Switzerland, Argentina, Belgium, Slovakia, South Korea, Israel, Colombia, Czech Republic, Australia, Thailand, Poland (unspecified route)
  • 28 Oct 2022 No recent reports of development identified for clinical-Phase-Unknown development in Breast-cancer(Diagnosis) in USA
  • 28 Oct 2022 No recent reports of development identified for clinical-Phase-Unknown development in Endometrial-cancer(Diagnosis) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top